Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies.
Jessica GarciaArnaud GauthierGaëlle LescuyerDavid BarthelemyFlorence GeiguerJulie BalandierDaniel L EdelsteinFrederick S JonesFrank HoltrupMickael DuruisseauEmmanuel GrolleauClaire Rodriguez-LafrassePatrick MerleSébastien CouraudLéa PayenPublished in: Molecular diagnosis & therapy (2021)
The OncoBEAMTM EGFR V2 is a sensitive, robust, and accurate assay that delivers reproducible results. Next-generation sequencing and BEAMing technologies act complementarily in the routine molecular screening. We show that using a next-generation sequencing assay, despite its lower sensitivity, enables the identification of rare EGFR alterations or resistance mechanisms (mutation, deletion, insertion, and copy number variation) to orient first- and second-line treatments.